NeoPharm CO., LTD. (KOSDAQ:092730)

South Korea · Delayed Price · Currency is KRW

22,250

-50 (-0.22%)

Oct 30, 2026, 3:30 PM KST

Market Cap	348.02B +30.2%
Revenue (ttm)	132.18B +11.1%
Net Income	27.82B +20.6%
EPS	1,778.81 +20.6%
Shares Out	15.64M
PE Ratio	12.51
Forward PE	9.55
Dividend	750.00 (3.37%)
Ex-Dividend Date	Dec 29, 2025

Volume	46,963
Open	22,300
Previous Close	22,300
Day's Range	21,600 - 22,800
52-Week Range	15,590 - 26,000
Beta	0.54
Analysts	Strong Buy
Price Target	30,500.00 (+37.08%)
Est. Earnings	Nov 13, 2026

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So... [Read more]

Industry Household & Personal Products

Sector Consumer Staples

Founded 2000

Employees 178

Stock Exchange KOSDAQ

Ticker Symbol 092730

Full Company Profile

Financial Performance

In 2025, NeoPharm CO., LTD.'s revenue was 132.18 billion, an increase of 11.07% compared to the previous year's 119.01 billion. Earnings were 27.82 billion, an increase of 20.63%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 092730 stock is "Strong Buy." The 12-month stock price target is ₩30,500, which is an increase of 37.08% from the latest price.

Price Target

₩30,500

(37.08% upside)

Analyst Consensus: Strong Buy

Stock Forecasts